Danaher Corporation · NYSE (us_market)
Healthcare · Diagnostics & Research · United States
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-01-27$250.59 RISE2025-04-08$174.64 PEAK2025-06-12$205.10 136d | -30.3% 71d | Missed | Missed | — | — | +17.4% 65d | Missed |
DROP2023-09-01$235.45 RISE2023-10-30$185.10 PEAK2024-01-08$234.86 129d | -21.4% 59d | Missed | Missed | — | — | +26.9% 70d | Missed |
DROP2023-01-23$245.57 RISE2023-05-16$199.46 PEAK2023-07-26$234.81 184d | -18.8% 113d | Missed | Missed | — | — | +17.7% 71d | Missed |
DROP2022-04-07$265.66 RISE2022-06-17$211.52 PEAK2022-08-15$268.04 130d | -20.4% 71d | Missed | Missed | — | — | +26.7% 59d | Missed |
DROP2021-12-31$291.68 RISE2022-05-11$210.20 PEAK2022-07-29$258.40 210d | -27.9% 131d | Missed | Missed | — | — | +22.9% 79d | Missed |
DROP2021-12-31$291.68 RISE2022-03-08$228.08 PEAK2022-04-07$265.66 97d | -21.8% 67d | Missed | Missed | — | — | +16.5% 30d | Missed |
DROP2020-01-30$149.87 RISE2020-03-23$107.62 PEAK2020-06-17$156.32 139d | -28.2% 53d | Missed | Missed | — | — | +45.3% 86d | Missed |
Despite Thermo Fisher Scientific's underperformance relative to the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Danaher Corporation (NYSE:DHR) is one of the best medical stocks to invest in according to billionaires. RBC Capital resumed coverage of Danaher Corporation (NYSE:DHR) with an Outperform rating on May 14, setting a price target of $200. The firm told investors in a research note that it sees the company’s growth recovering with an improvement in […]
Danaher Corporation (NYSE:DHR) is one of the best medical stocks to invest in according to billionaires. RBC Capital resumed coverage of Danaher Corporation (NYSE:DHR) with an Outperform rating on May 14, setting a price target of $200. The firm told investors in a research note that it sees the company’s growth recovering with an improvement in […]
Looking back on research tools & consumables stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Danaher (NYSE:DHR) and its peers.
Looking back on research tools & consumables stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Danaher (NYSE:DHR) and its peers.
Danaher (DHR) drew fresh attention after strong first quarter results, with adjusted earnings per share ahead of expectations and full year guidance raised. This combination supported renewed interest in the stock. See our latest analysis for Danaher. Despite the positive Q1 surprise and raised guidance, Danaher’s share price return is still down 25.35% year to date and the 1 year total shareholder return is down 6.15%. Recent momentum therefore remains fragile. If earnings driven moves in...
Danaher (DHR) drew fresh attention after strong first quarter results, with adjusted earnings per share ahead of expectations and full year guidance raised. This combination supported renewed interest in the stock. See our latest analysis for Danaher. Despite the positive Q1 surprise and raised guidance, Danaher’s share price return is still down 25.35% year to date and the 1 year total shareholder return is down 6.15%. Recent momentum therefore remains fragile. If earnings driven moves in...
In recent weeks, Danaher reported strong Q1 2026 results with an earnings beat, raised full‑year adjusted EPS guidance, and highlighted 7% core revenue growth in its Biotechnology segment, while also advancing its pending US$9.90 billion Masimo acquisition and showcasing innovation such as the AI‑native Genedata Vico platform and carbon‑capture filtration pilots at Pall. Together, these developments underscore how Danaher is reinforcing its position across diagnostics, bioprocessing, and...
In recent weeks, Danaher reported strong Q1 2026 results with an earnings beat, raised full‑year adjusted EPS guidance, and highlighted 7% core revenue growth in its Biotechnology segment, while also advancing its pending US$9.90 billion Masimo acquisition and showcasing innovation such as the AI‑native Genedata Vico platform and carbon‑capture filtration pilots at Pall. Together, these developments underscore how Danaher is reinforcing its position across diagnostics, bioprocessing, and...
Akre Capital Management Q1 2026 13F: portfolio down to $6.13B, big trims in MA/V/MCO/KKR, new CRM/NOW adds, stake boostsâread now.
Pall Corporation, a Danaher subsidiary, received government funding to pilot advanced filtration technology for carbon capture at engineering scale. Genedata, also part of Danaher, launched Genedata Vico, an AI native CMC solution co developed with major pharma partners and recognized with industry awards. For investors watching NYSE:DHR at a share price of $173.33, these updates highlight activity in both climate focused filtration and biopharma software. The stock is up 5.3% over the past...
Pall Corporation, a Danaher subsidiary, received government funding to pilot advanced filtration technology for carbon capture at engineering scale. Genedata, also part of Danaher, launched Genedata Vico, an AI native CMC solution co developed with major pharma partners and recognized with industry awards. For investors watching NYSE:DHR at a share price of $173.33, these updates highlight activity in both climate focused filtration and biopharma software. The stock is up 5.3% over the past...
Barronâs Oil & Blue Chip Tips for May 2026 highlight 20 stocks, with 11 deemed 'safer' based on free cash flow yields exceeding dividend yields. Read the full list here.
The XAI Madison Equity Premium Income Fund currently trades at an 8.86% discount, with a 12.29% distribution yield. Click here to learn more about MCN.
MELVILLE, N.Y., May 22, 2026--Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected William K. "Dan" Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel succeeds Stanley M. Bergman, who retired from the Board following 44 years as a Director of Henry Schein and was named Chairman Emeritus in recognition of his extraordinary contr
Eagle Capital Management, an investment management company, released its first quarter 2026 investor letter. A copy of the letter is available to download here. The letter notes that individual stocks and subsectors are now more reactive to sentiments, reducing market efficiency but creating opportunities to add value. Over the last decade, multi-asset managers, or pods, […]
Eagle Capital Management, an investment management company, released its first quarter 2026 investor letter. A copy of the letter is available to download here. The letter notes that individual stocks and subsectors are now more reactive to sentiments, reducing market efficiency but creating opportunities to add value. Over the last decade, multi-asset managers, or pods, […]
Generation IM Q1 2026 13F: portfolio drops to $11.16B; top holdings MSFT, AMZN & GOOGL; big buys/sells and new picks.
DHR's Biotechnology segment posts 7% core revenue growth as bioprocessing demand stayed strong and equipment orders jumped despite headwinds.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| DHR | +4.29% | -11.33% | -20.20% | -3.81% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +1.32% | -5.61% | -16.76% | -16.50% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 27.89M | $5.30B | 0.18% | Added+0.8% | 2026-03-31 |
| FidelityFMR | fundamental | 22.53M | $4.27B | 0.23% | Added+15.5% | 2026-03-31 |
| Wellington | fundamental | 14.77M | $2.80B | 0.52% | Trimmed-2.0% | 2026-03-31 |
| CapResearch | fundamental | 8.90M | $1.69B | 0.26% | Added+1445.9% | 2026-03-31 |
| TwoSigma | quant | 1.86M | $352.43M | 0.28% | Added+6282.5% | 2026-03-31 |
| DEShaw | quant | 1.43M | $270.80M | 0.16% | Added+162.8% | 2026-03-31 |
| RenTech | quant | 678.8K | $128.70M | 0.20% | New | 2026-03-31 |
| ThirdPoint | activist | 525.0K | $99.54M | 4.78% | Trimmed-12.5% | 2026-03-31 |
| Bridgewater | macro | 25.3K | $4.81M | 0.02% | Trimmed-20.1% | 2026-03-31 |
| TRowePrice | fundamental | 15.35M | $2.91M | 0.34% | Trimmed-3.9% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-19 | Lamanna Charles W | Director | A Grant / award(deriv) | 1,699 | — | +$0 |
| 2026-05-19 | Lamanna Charles W | Director | A Grant / award | 680 | — | +$0 |
| 2026-05-19 | Dewan Feroz | Director | A Grant / award(deriv) | 1,699 | — | +$0 |
| 2026-05-19 | Dewan Feroz | Director | A Grant / award | 680 | — | +$0 |
| 2026-05-19 | Zerhouni Elias A. | Director | A Grant / award(deriv) | 1,699 | — | +$0 |
| 2026-05-19 | Zerhouni Elias A. | Director | A Grant / award | 680 | — | +$0 |
| 2026-05-19 | List Teri | Director | A Grant / award(deriv) | 1,699 | — | +$0 |
| 2026-05-19 | List Teri | Director | A Grant / award | 680 | — | +$0 |
| 2026-05-19 | Sanders A Shane | Director | A Grant / award(deriv) | 1,699 | — | +$0 |
| 2026-05-19 | Sanders A Shane | Director | A Grant / award | 680 | — | +$0 |
| 2026-05-19 | SPOON ALAN G | Director | A Grant / award(deriv) | 1,699 | — | +$0 |
| 2026-05-19 | SPOON ALAN G | Director | A Grant / award | 680 | — | +$0 |
| 2026-05-19 | Stevens Raymond C | Director | A Grant / award(deriv) | 1,699 | — | +$0 |
| 2026-05-19 | Stevens Raymond C | Director | A Grant / award | 680 | — | +$0 |
| 2026-05-19 | Couchara Georgeann | SVP, Human Resources | F Tax withholding | 281 | $161.91 | −$45.5K |
| 2026-05-19 | FILLER LINDA | Director | A Grant / award(deriv) | 1,699 | — | +$0 |
| 2026-05-19 | FILLER LINDA | Director | A Grant / award | 680 | — | +$0 |
| 2026-05-04 | SPOON ALAN G | Director | M Option exercise(deriv) | 3,298 | — | +$0 |
| 2026-05-04 | SPOON ALAN G | Director | S Open-market sale | 1,358 | $174.67 | −$237.2K |
| 2026-05-04 | SPOON ALAN G | Director | M Option exercise | 3,298 | $71.88 | +$237.1K |
| 2026-04-28 | Dewan Feroz | Director | A Grant / award(deriv) | 188 | $177.25 | +$33.3K |
| 2026-04-28 | SPOON ALAN G | Director | A Grant / award(deriv) | 252 | $177.25 | +$44.7K |
| 2026-04-28 | FILLER LINDA | Director | A Grant / award(deriv) | 20 | $177.25 | +$3.6K |
| 2026-04-28 | Zerhouni Elias A. | Director | A Grant / award(deriv) | 260 | $177.25 | +$46.0K |
| 2026-04-28 | List Teri | Director | A Grant / award(deriv) | 17 | $177.25 | +$3.1K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-21upcoming | 1.83 | — | — |
| 2026-04-21 | 1.94 | 2.06 | +6.45% |
| 2026-01-28 | 2.19 | 2.23 | +1.99% |
| 2025-10-21 | 1.72 | 1.89 | +9.78% |
| 2025-07-22 | 1.18 | 0.77 | -34.56% |
| 2025-04-22 | 1.64 | 1.88 | +14.38% |
| 2025-01-29 | 2.16 | 2.14 | -1.12% |
| 2024-10-22 | 1.57 | 1.71 | +8.94% |
| 2024-07-23 | 1.57 | 1.72 | +9.30% |
| 2024-04-23 | 1.71 | 1.92 | +12.41% |
| 2024-01-30 | 1.91 | 2.09 | +9.15% |
| 2023-10-24 | 1.88 | 2.02 | +7.55% |
| 2023-07-25 | 2.02 | 2.05 | +1.73% |
| 2023-04-25 | 2.26 | 2.36 | +4.36% |
| 2023-01-24 | 2.55 | 2.87 | +12.62% |
| 2022-10-20 | 2.25 | 2.56 | +13.54% |